FASCINATION ABOUT MBO128

Emily Bodnar’s ranking is predicated around the anticipation of major milestones for Agenus in the approaching 12 months, significantly the potential filing of a Biologics License Application (BLA) for his or her guide drug candidate, botensilimab (bot). Agenus has dosed around 900 patients with bot across different reliable tumors, demonstrating